[Alpha-blockers in therapy of arterial hypertension. No longer the drug of first choice].
Faulhaber
H D
HD
Max-Delbrück-Zentrum für Molekulare Medizin, Berlin-Buch. faulhaber@fvk-berlin.de
D000317:Adrenergic alpha-Antagonists / Q000008:administration & dosage* / Q000009:adverse effects; D000368:Aged; D000959:Antihypertensive Agents / Q000008:administration & dosage* / Q000009:adverse effects; D002423:Cause of Death; D002752:Chlorthalidone / Q000008:administration & dosage / Q000009:adverse effects; D017292:Doxazosin / Q000008:administration & dosage / Q000009:adverse effects; D004359:Drug Therapy, Combination; D005260:Female; D006333:Heart Failure / Q000139:chemically induced / Q000401:mortality; D006801:Humans; D006973:Hypertension / Q000188:drug therapy* / Q000209:etiology / Q000401:mortality; D008297:Male; D008875:Middle Aged; D015337:Multicenter Studies as Topic; D016032:Randomized Controlled Trials as Topic
D000317:Adrenergic alpha-Antagonists; D000959:Antihypertensive Agents; D017292:Doxazosin; D002752:Chlorthalidone